The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease
Lesley A Graff,Rose Geist,M Ellen Kuenzig,Eric I Benchimol,Gilaad G Kaplan,Joseph W Windsor,Alain Bitton,Stephanie Coward,Jennifer L Jones,Kate Lee,Sanjay K Murthy,Juan-Nicolás Peña-Sánchez,Laura E Targownik,Nazanin Jannati,Tyrel Jones May,Tasbeen Akhtar Sheekha,Tal Davis,Jake Weinstein,Ghaida Dahlwi,James H B Im,Jessica Amankwah Osei,Noelle Rohatinsky,Sara Ghandeharian,Quinn Goddard,Julia Gorospe,Shira Gertsman,Michelle Louis,Richelle Wagner,Colten Brass,Rhonda Sanderson,Charles N Bernstein
DOI: https://doi.org/10.1093/jcag/gwad012
2023-09-01
Journal of the Canadian Association of Gastroenterology
Abstract:Abstract Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even higher when considering mental health symptoms, as nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. Rates of these symptoms were much higher during periods of disease activity, more common in women than men, and more common in Crohn’s disease than ulcerative colitis. There is robust evidence of the detrimental effects of comorbid depression and anxiety on the subsequent course of IBD based on longitudinal studies tracking outcomes over time. However, psychiatric disorders and IBD have bidirectional effects, with each affecting risk of the other. Elevated mental health concerns have been consistently associated with greater healthcare utilization and costs related to IBD. There is some signal that low resilience in adolescence could be a risk factor for developing IBD and that enhancing resilience may improve mental health and intestinal disease outcomes in IBD. Psychological therapies used to treat anxiety and depression occurring in the context of IBD have been shown to significantly improve the quality of life for persons with IBD and reduce anxiety and depression. There is less evidence in regard to the impact of psychotropic medications on mental health or disease outcomes in persons with IBD. There is consensus, however, that mental health must be addressed as part of comprehensive IBD care for children and adults.